Page 53 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

36. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase
inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists'
Collaboration. JAMA 1998;280(20):1777-82.
37. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease.
Cochrane Database Syst Rev 2004(4):CD001191.
38. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil
treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Lancet 2004;363(9427):2105-15.
39. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil
in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord
1999;10(3):237-44.
40. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized,
double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology
2001;57(4):613-20.
41. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy
and safety of donepezil on cognitive and global function in patients with Alzheimer's
disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020
Study Group. Dement Geriatr Cogn Disord 2000;11(6):299-313.
42. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-
controlled preservation of function survival study of donepezil in AD patients. Neurology
2001;57(3):481-8.
43. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global
function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study.
Donepezil Study Group. Arch Intern Med 1998;158(9):1021-31.
44. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind,
placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study
Group.[see comment]. Neurology 1998;50(1):136-45.
45. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's
disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.
The Donepezil Study Group. Dementia 1996;7(6):293-303.
46. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil
in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol
2004;61(12):1852-6.
47. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A
randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil
in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc
2001;49(12):1590-9.
48. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year,
randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
Neurology 2001;57(3):489-95.
49. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine
prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Dement Geriatr Cogn Disord 2005;20(2-3):120-32.
50. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized,
placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Neurology 2000;54(12):2261-8.

Alzheimer's Drugs Page 53 of 205